VIP (Vasoactive Intestinal Peptide) 10mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of VIP supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF112025069

Key analytical results include:

• Assay Content: 9.71 mg
• Identification – Retention Time: 0.982
• Identification – Spectrum: 991
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

VIP is a synthetic peptide research compound frequently studied in controlled laboratory environments investigating peptide signalling pathways and receptor-mediated cellular communication systems.

The compound is a laboratory form of vasoactive intestinal peptide, a naturally occurring neuropeptide that functions as a signalling molecule in multiple biological systems.

This preparation contains 10 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined peptide structure and stable analytical profile, VIP has become a commonly referenced compound in experimental peptide signalling research.

Compound Overview

VIP, short for vasoactive intestinal peptide, is a neuropeptide belonging to the secretin/glucagon peptide family and is widely studied in biochemical research exploring receptor-mediated signalling pathways.

Within laboratory research models, VIP is known to interact with specific G-protein coupled receptors that regulate intracellular signalling processes.

Because of its role in peptide signalling systems, the compound is frequently used in experimental studies investigating cellular communication, regulatory signalling networks and peptide receptor interaction dynamics.

Historical Background and Scientific Context

VIP was first identified in the early 1970s during research into intestinal peptide hormones and neuropeptide signalling systems.

As biochemical research techniques advanced, scientists discovered that VIP participates in a wide range of peptide signalling pathways within the nervous and endocrine systems.

Due to its involvement in receptor-mediated signalling networks, the peptide became an important compound in laboratory studies exploring molecular communication systems within cells.

Mechanistic Focus in Research

Within experimental laboratory settings, VIP is commonly studied in relation to peptide receptor signalling and intracellular regulatory pathways.

Research investigations commonly explore the compound in experimental models examining:

• Peptide receptor signalling pathways
• G-protein coupled receptor interaction
• Intracellular signalling cascades
• Cellular communication networks
• Neuropeptide signalling systems
• Comparative peptide signalling research
• Molecular regulatory pathway analysis

These experimental models allow scientists to investigate molecular regulatory mechanisms involved in peptide-mediated signalling and cellular communication.

Research Applications

In controlled research environments, VIP may be utilised in experimental models designed to explore neuropeptide signalling systems and receptor-mediated regulatory pathways.

Examples of research applications include:

• Cell signalling pathway investigation
• Peptide receptor interaction research
• Intracellular signalling network modelling
• Comparative peptide compound studies
• Molecular regulatory pathway analysis
• Neuropeptide signalling research
• Controlled in vitro peptide signalling studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Independently analysed by Liquilabs s.r.o. Czechia
• Greater than 99.8 percent purity
• Endotoxins below 0.001 EU per mg
• No detectable heavy metals or microbial contamination
• Neuroregulatory and neuroimmune signalling research peptide
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.